NHS doctors in England able to prescribe pertuzumab after price carve agreed with makerA drug that can give women suffering from incurable advanced breast cancer an extra 16 months of life has been approved for general spend in the NHS in England after a price carve was negotiated with the manufacturer.
The decision by Nice,the National Institute for Health and Care Excellence, to give the green light for NHS doctors to spend pertuzumab, and sold under the brand name of Perjeta by the Swiss drug company Roche,was enthusiastically welcomed by breast cancer charities.
Continue reading...
Source: guardian.co.uk